While our findings suggest that GATA2MUT and TET2MUT both converge at rebalancing the increased expression of GATA2 in CEBPADM AML, patients with CEBPADM and GATA2MUT have a more favorable prognosis16,31–33,49 than patients harboring the CEBPADM and TET2MUT combination16,17. The gene discussed is GATA2; the disease is acute myeloid leukemia.